Institutional shareholders of AsiaPharm Group Ltd. (SI: ASPH), a Singapore-listed biopharma whose operations are in China, will oppose a recently announced deal that proposed to take the company private. To win approval of the private equity deal, the company must win the support of shareholders who hold at least 90% of the outstanding shares. Three money managers, whose collective holdings surpass the 10% threshold, have announced they will oppose the deal. More details...